Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.54 |
| ▸ | KLK7 | P49862 | 4/20 | 0.53 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.53 |
| ▸ | CTSS | P25774 | 2/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.43 |
| ▸ | CDC25B | P30305 | 4/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.43 |
| ▸ | CDC25A | P30304 | 2/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9929698 | 1.00 | PPARA (0.54) | PPARAKLK7KLK5CTSSPPARG | |
| SCHEMBL3746299 | 0.83 | PPARA (0.62) | PPARAKLK7KLK5CTSSPPARG | |
| SCHEMBL9929074 | 0.82 | PPARA (0.47) | PPARAKLK7KLK5CTSSPPARG | |
| SCHEMBL9929072 | 0.82 | PPARA (0.47) | PPARAKLK7KLK5CTSSPPARG | |
| SCHEMBL27883346 | 0.82 | CTSS (0.38) | PPARAKLK7KLK5CTSSCTSL | |
| SCHEMBL6582704 | 0.79 | PPARA (0.59) | PPARAKLK7KLK5CTSSPPARG | |
| SCHEMBL7352624 | 0.76 | PPARA (0.56) | PPARAKLK7KLK5CTSSPPARG | |
| SCHEMBL9929823 | 0.76 | PPARA (0.46) | PPARAKLK7KLK5CTSSPPARG | |
| SCHEMBL9929824 | 0.76 | PPARA (0.46) | PPARAKLK7KLK5CTSSPPARG | |
| SCHEMBL13198526 | 0.76 | PPARA (0.63) | PPARAKLK7KLK5CTSSPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796269-B2 | Crystalline 2-(3,5-Bis(trifluoromethyl)phenyl)-N-(4-(4-fluoro-2-methylphenyl)-6-((7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl)pyridin-3-yl)-N,2-dimethyl-propanamide of the formula (I), their use in therapy, and process for the preparation of the same | NERRE THERAPEUTICS LIMITED (GB) | 2014-08-05 | — | — | US | disclosed |
| EP-2470545-B1 | ANHYDRATE FORMS OF A PYRIDINE DERIVATIVE | NERRE THERAPEUTICS LTD (GB) | 2013-10-09 | — | — | EP | disclosed |
| US-20120157450-A1 | Anhydrate Forms Of A Pyridine Derivative | KaNDy Therapeutics Limited (GB) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157450-A1 | Anhydrate Forms Of A Pyridine Derivative | CA4, CA2, CA7 | PPARA 695/4885KLK7 933/4885KLK5 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.